Gutted adenoviral vector growth using E1/E2b/E3-deleted helper viruses

Journal of Gene Medicine

Volumn 4, Issue 5, 2002, Pages 480-489

  Barjot, Catherine ^a,d   Hartigan O'Connor, Dennis ^a,b,c   Salvatori, Giovanni ^a,e   Scott, Jeannine M ^a,c   Chamberlain, Jeffrey S ^a,b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d INRA UMR 703   (France)

^e NONE   (Italy)

Author keywords

Adenovirus; Duchenne muscular dystrophy; Dystrophin; Gene therapy; Gutted adenovirus; Helper virus

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; CRE RECOMBINASE; DNA POLYMERASE; DYSTROPHIN; E2B PROTEIN; E3 PROTEIN; GLYCOPROTEIN E1; UNCLASSIFIED DRUG; VIRUS PROTEIN; INTEGRASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LINE; COLORIMETRY; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; GENE DELETION; GENE THERAPY; GENETIC COMPLEMENTATION; GENETIC TRANSFECTION; HELPER VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VIVO STUDY; LOXP SITE; MOUSE; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SAFETY; SIGNAL TRANSDUCTION; VIRAL CONTAMINATION; VIRAL GENE DELIVERY SYSTEM; VIROGENESIS; VIRUS REPLICATION; ADENOVIRUS; GENE VECTOR; GENETICS; ISOLATION AND PURIFICATION;

ADENOVIRIDAE;

ADENOVIRIDAE; ADENOVIRUS EARLY PROTEINS; GENETIC VECTORS; HELPER VIRUSES; HUMANS; INTEGRASES; VIRAL PROTEINS;

EID: 0036725905     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.305     Document Type: Article

References (33)

1. Hitt MM, Graham FL. Adenovirus vectors for human gene therapy. Adv Virus Res 2000; 55: 479-505.
2. Mitani K, Graham FL, Caskey CT, et al. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci U S A 1995; 92: 3854-3858.
3. Kumar-Singh R, Chamberlain JS. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum Mol Genet 1996; 5: 913-921.
4. Fisher KJ, Choi H, Burda J, et al. Recombinant adenovirris deleted of all viral genes for gene therapy of cystic fibrosis. Virology 1996; 217: 11-22.
5. Hartigan-O'Connor D, Barjot C, Salvatori G, et al. Growth and P urification of gutted adenoviral vectors. Methods Enzymol 2002; in press.
6. Parks RJ, Chen L, Anton M, et al. A helper-dependent adenovirus vector system: removal of helper virus by cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A 1996; 93: 13 565 -13 570.
7. Hardy S, Kitamura M, Harris-Stansil T, et al. Construction of adenovirus vectors through Cre-lox recombination. J Virol 1997; 71: 1842-1849.
8. Sandig V, Youil R, Bett AJ, et al. Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc Natl Acad Sci U S A 2000; 97: 1002-1007.
9. Zou L, Zhou H, Pastore L, et al. Prolonged transgene expression mediated by a helper-dependent adenoviral vector (hdAd) in the central nervous system. Mol Ther 2000; 2: 105-113.
10. Bristol JA, Shirley P, Idamakanti N, et al. In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice. Mol Ther 2000; 2: 223-232.
11. Tao N, Gao GP, Parr M, et al. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 2001; 3: 28-35.
12. Schnell MA, Zhang Y, Tazelaar J, et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther 2001; 3: 708-722.
13. Amalfitano A, Hauser MA, Hu H, et al. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol 1998; 72: 926-933.
14. Amalfitano A, Chamberlain JS. Isolation and characterization of packaging cell lines that co-express the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy. Gene Ther 1997; 4: 258-263.
15. Hartigan-O'Connor D, Amalfitano A, Chamberlain JS. improved production of gutted adenovirus in cells expressing adenovirus preterminal protein and DNA polymerase. J Virol 1999; 73: 7835-7841.
16. Hartigan-O'Connor D, Barjot C, Salvatori G, et al. Efficient rescue of gutted adenovirus genomes allows rapid production of concentrated stocks without negative selection. Hum Gene Ther 2002; in press.
17. Hu H, Serra D, Amalfitano A. Persistence of an [El-, polymerase-] adenovirus vector despite transduction of a neoantigen into immune-competent mice. Hum Gene Ther 1999; 10: 355-364.
18. Amalfitano A, Begy CR, Chamberlain JS. Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors. Proc Natl Acad Sci U S A 1996; 93: 3352-3356.
19. O'Gorman S, Dagenais NA, Qian M, et al. Protamine-Cre recombinase transgenes efficiently recombine target sequences in the male germ line of mice, but not in embryonic stem cells. Proc Natl Acad Sci U S A 1997; 94: 14 602-14 607.
20. MacGregor GM, Nolan GP, Fiering S, et al. Use of E. coli LacZ (β-galactosidase) as a reporter gene. In Methods Molecular Biology, vol 7. Gene Transfer and Expression Protocols Murray EJ (ed.). Human Press Inc.: Clifton, NJ, 1991; 217-225.
21. Hirt B. Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol 1967; 26: 365-369.
22. Graham FL, Smiley J, Russell WC, et al. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59-72.
23. Morral N, Parks R, Zhou H, et al. High doses of a helper-dependent adenoviral vector yield supraphysiological levels α1-antitrypsin with negligible toxicity. Hum Gene Ther 1998; 9 2709-2716.
24. Chen HH, Mack LM, Kelly R, et al. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci U S A 1997; 94: 1645-1650.
25. Morsy MA, Gu M, Motzel S, et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci U S A 1998; 95: 7866-7871.
26. Schiedner G, Morral N, Parks RJ, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998; 18 180-183.
27. Pastore L, Morral N, Zhou HS, et al. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum Gene Ther 1999; 10: 1773-1781.
28. O'Neal WK, Zhou H, Mortal N, et al. Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector. Mol Med 2000; 6: 179-195.
29. Hartigan-O'Connor D, Kirk CJ, Crawford R, et al. Immune evasion by muscle specific gene expression in dystrophic muscle. Mol Ther 2001; 4: 525-533.
30. Yeh P, Dedieu JF, Orsini C, et al. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J Virol 1996; 70: 559-565.
31. Fallaux FJ, Bout A, van der Velde I, et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998; 9: 1909-1917.
32. Lusky M, Christ M, Rittner K, et al. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J Virol 1998; 72: 2022-2032.
33. Gorziglia MI, Lapcevich C, Roy S, et al. Generation of an adenovirus vector lacking E1, E2a, E3, and all of E4 except open reading frame 3. J Virol 1999; 73: 6048-6055.